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Abstract
FOXO transcription factors are an important, conserved family of regulators of cellular processes including metabolism, cell-
cycle progression, apoptosis and stress resistance. They are required for the efficacy of several of the genetic interventions
that modulate lifespan. FOXO activity is regulated by multiple post-translational modifications (PTMs) that affect its
subcellular localization, half-life, DNA binding and transcriptional activity. Here, we show how a mathematical modelling
approach can be used to simulate the effects, singly and in combination, of these PTMs. Our model is implemented using
the Systems Biology Markup Language (SBML), generated by an ancillary program and simulated in a stochastic framework.
The use of the ancillary program to generate the SBML is necessary because the possibility that many regulatory PTMs may
be added, each independently of the others, means that a large number of chemically distinct forms of the FOXO molecule
must be taken into account, and the program is used to generate them. Although the model does not yet include detailed
representations of events upstream and downstream of FOXO, we show how it can qualitatively, and in some cases
quantitatively, reproduce the known effects of certain treatments that induce various single and multiple PTMs, and allows
for a complex spatiotemporal interplay of effects due to the activation of multiple PTM-inducing treatments. Thus, it
provides an important framework to integrate current knowledge about the behaviour of FOXO. The approach should be
generally applicable to other proteins experiencing multiple regulations.
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Introduction
The FOXO (Forkhead Box, type O) family of transcription
factors (TFs) cause changes in gene expression to implement a
cellular stress response programme, and an increase in their
activity is a consequence of many of the genetic interventions that
extend lifespan in model organisms. FOXO transcription factors
are active when an organism is fasting, whereas feeding causes the
activation of the Insulin- and Insulin-like Signalling (IIS) pathway,
and in particular of Akt/PKB, which negatively regulates FOXO
TFs by phosphorylations that cause translocation to the cytoplasm,
thus suppressing their transcriptional activity. However, the
location, synthesis/degradation and transcriptional behaviour
can all be modified by signals from a variety of cellular signalling
pathways, which are integrated by FOXO as a net response to the
total set of modifications (phosphorylations, acetylations and
ubiquitinations), that it undergoes. Integrating this knowledge
within an extensible framework would provide a valuable means to
organise the information and to explore the role of the
modifications.
FOXO transcription factors are highly evolutionarily conserved
in multicellular animals. There are four closely related FOXO
paralogues in mammals, FOXO1 (formerly FKHR), FOXO3
(formerly FKHRL1; often known as FOXO3A), FOXO4
(formerly AFX) and FOXO6 (for the human genes, Ensembl
accession codes ENSG00000150907, ENSG00000118689,
ENSG00000184481 and ENSG00000204060, and for human
proteins, UniProt accession codes Q12778, O43524, P98177 and
A8MYZ6, respectively). All are ubiquitously expressed, but
FOXO1 is particularly highly expressed in adipose tissue, FOXO3
in the brain, FOXO4 in the heart, and FOXO6 in the developing
brain [1]. FOXO1 is particularly associated with the regulation of
metabolism [2] and homozygous deletion is embryonic lethal,
while FOXO3 homozygous knockout mice are viable but infertile,
and FOXO4 deletions are also viable with no apparent
phonotype. In Caenorhabditis elegans the FOXO orthologue is
produced from the daf-16 gene (wormbase WBGene00000912). In
Drosophila melanogaster, there is again a single dFOXO gene (flybase
FBgn0038197). Proteins in the FOXO family are more distantly
related to other FOX-domain containing TFs, such as the FOXA
family, which themselves have a role in ageing [3]. The genes
regulated by FOXO family members have been studied, both
by high-throughput methods (mainly microarrays ([4–13] but
also proteomics [14]) and studies concentrating on one or a
few genes. In mammals, these include Bim [15–18]; MnSOD
(SOD2) [19]; GADD45 [20]; p21cip1/waf1 (CDKN1A) [21];
p15ink4b (CDKN2B) [22]; CITED-2 (involving interactions with
HIF) [23]; p27kip1 (CDKN1B) [16,19,24,25]; autophagy [26];
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InsR [30]; in C elegans: MnSOD (SOD2, SOD3 in mammals),
[19,31]; daf-15 (raptor) [32]; gadd45, p27kip1, and FasL [33,34].
FOXO TFs may also regulate their own expression [35,36] as well
as being under the control of E2F1 [37]. Their action as TFs may
be modulated by association with other factors such as p53 (in the
regulation of SIRT1 [29]), RunX3 (in the regulation of Bim) [18]
and Smad 3/4 and FOXG (in the regulation of p21cip1/waf1)
[21,22]. Indeed, through these associations, FOXOs may
influence transcription independently of DNA binding. The
individually studied FOXO-regulated genes tend to fall into
categories such as stress resistance (SOD2, catalase), negative
regulation of the cell cycle (p27kip1, GADD45), and apoptosis
(FasL, Bim). A comparative genomics study [38] of microarray
data from flies, worms and mice has shown that, while there
appears to be little conservation of particular orthologous genes, at
least between mammals and invertebrates, there is consistent
down-regulation of genes associated with protein biosynthesis and
up-regulation of genes associated with sugar catabolism, energy
generation, and several categories of cellular detoxification.
Additionally, single-gene studies have shown up some further
cross-species similarities e.g. InsR, p27kip1, and Bim.
In Figure 1A, we show a multiple sequence alignment of FOXO
family members from human (Homo sapiens), mouse (Mus musculus),
Xenopus leavis, Dario rerio, Drosophila and C elegans. There are some
regions of conservation throughout, especially in the DNA-binding
domain (expanded region). Some of the modifiable sites in this
domain are highlighted, along with an indication of the enzyme
that modifies them. It is clear that there a great many regulators of
FOXO (among them Akt, CDK2, CK1, JNK, IKK, AMPK,
SIRT1 and CBP/P300), and a great many modifiable sites. The
multiple sequence alignment is available as supplementary dataset
S1. In several cases, the modifiable amino acid contacts DNA
directly, making it obvious how a covalent change could alter
DNA-binding behaviour; this is shown in Figure 1B, a represen-
tation of the structure of Human FOXO3 bound to DNA (PDB
accession 2UZK [39]); more recently, the effect of acetylation on
binding has been shown directly [40].
FOXO is implicated in many of the interventions that extend
lifespan in worms, flies and mice, particularly genetic interventions
in the IIS pathway and some protocols of dietary restriction (DR).
Overexpression of FOXO itself extends lifespan moderately in flies
[41,42], as do the overexpression of the regulators JNK in flies
[43] and worms [44], MST in worms [45], AMPK in worms [10],
and sir2.1 in worms [46]. Lifespan is extended by many loss-of-
function mutations of daf-2, (the C elegans insulin-like receptor)
and other molecules in the IIS pathway in a FOXO/daf-16
dependent manner. Similarly, lifespan is extended by DR in ways
that, depending on the protocol, may be dependent on FOXO (e.g
sDR, [10]), partially dependent on it (IF, [47]) or independent of it
[48]. See Greer et al. [49] for a recent review of methods of DR in
C elegans. Certain FOXO hapolotypes [50–52] and SNPs in the
FOXO3 gene have been found to be associated with human
longevity [53], although interestingly the SNPs are all found in
intronic regions, and do not seem to introduce or remove sequence
features related to splicing, so it is not clear how they have their
effect.
Many reviews of the behaviour and role of FOXO are available,
related to its PTMs [54], its role in ageing and the maintenance of
homeostasis [55,56], metabolism [2], cancer and apoptosis [57],
the immune system [58], cancer [59], ageing and cancer [1], its
structure/function relationships [60], interaction partners [61],
and subcellular localization and transcription [62]. Karpac and
Jasper [63] review the interaction between IIS and stress signalling
through JNK, while van der Horst et al [64] and Levine et al [65]
review the interaction with stress signalling more generally, and
compare and contrast the roles of FOXO and p53. What is clear is
that the interpretation of the multiple complex regulations and
interactions will be much assisted by a quantitative modelling
approach.
To our knowledge FOXO has not been previously the subject of
computational modeling, though other transcription factors have,
for example the SMAD2/SMAD4 complex [66], MSN2/4
[67,68], NF-kB [69], p53 [70,71]. The forkhead homologue from
fission and budding yeast, FKH2, has been treated as part of a
wide survey of regulation of the cell cycle by coupled transcription
and phophorylation [72], though its regulation was not modelled
in detail. Several of the above references include the modelling of
nuclear-cytoplasmic shuttling, which is a key regulatory mecha-
nism of many TFs, including FOXO.
It is clear that FOXO has important roles in ageing, nutrient
response and stress response pathways; and also that the large
number of regulations that it undergoes and their different and
often contradictory effects, make it difficult to understand the
system. Hence, we believe that it is a good candidate for
computational modelling, which, by integrating information from
diverse sources and making possible a quantitative description, has
the ability to resolve some of these difficulties [73]. We have
produced a model in which the level of various modifiers of
FOXO (activities of modifying enzymes) are set as inputs, and in
which the behaviour of the FOXO in terms of localization, protein
level and the transcriptional response are the outputs. Because of
the complexity of the interaction of FOXO PTMs, this already
produces interesting behaviour, and provides the core of future
models in which the concentrations and activities of the modifying
enzymes will themselves be dynamic variables, set by extracellular
signals or by feedback regulation due, directly or indirectly, to
genes regulated by FOXO, and the transcriptional output will
include the response of multiple genes.
Methods
There are two problems to be faced in modelling the regulation
of FOXO. Firstly, it is necessary to choose a model structure that
simplifies the large (and still not fully elucidated) set of PTMs,
while still retaining enough information to describe all the relevant
regulations. Secondly, appropriate parameters must be set for the
reactions, even though detailed kinetic measurements are often not
available.
The first problem is a consequence mainly of the large
number of independent PTMs, which lead to a need to include
many species to describe all the combinations. This can be
appreciated by considering Figure 2A, which shows a fairly
complete (but not exhaustive) list of the known modifiable
residues of mammalian FOXOs [54]. If the model architecture
mirrored this directly, then, (since each of the N sites can have
its covalent modification presento ra b s e n ti n d e p e n d e n to fa l l
the others), it would be necessary to include a species in the
model to represent each combination of PTMs, leading to 2
N
FOXO species (chemically different molecules); and, in
addition, each could be present in the three compartments of
the cytoplasm, nucleus or bound to DNA (transcriptionally
active), making 362
N species in total. Each of these species
c o u l db ep r e s e n ti nac o p yn u m b e ro f0 ,1 ,2 ,…a te a c ht i m e
point in the simulation. For the set of N=27 modifications in
Figure 2A, this would result in approximately 10
8 species, an
excessively large number, even before all the reactions to
interconvert them are considered. However, simplifications can
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the behaviour of FOXO. This usually means all those made by
a particular modifying enzyme or enzymes. So, for example, to
a good approximation the three residues modified by Akt (T32,
S253 and S315 in Human FOXO3) must all be phosphorylated
before the effects are seen, which are to enhance export of
Figure 1. Sequence alignment and structure of FOXO. A: Multiple sequence alignment of FOXOs from human, mouse, zebrafish, Xenopus,
Drosophila, C elegans, together witha schematic diagram based on figure 2 of Calnan and Brunet 2008[54]. NES=Nuclear Export Sequence; NLS=Nuclear
Localization Sequence.The Forkhead domain is expanded and conserved regulatory sites are indicated. The alignment was made with T-Coffee [136] and
the graphic made with Jalview [137]. B: FOXO3 bound to DNA; 2UZK [39]. The graphic was made with PyMOL (DeLano Scientific, Palo Alto, CA, USA).
doi:10.1371/journal.pone.0011092.g001
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affinity for DNA [77] and to increase its degradation rate [78].
Hence, eight combinations of phosphorylations of 3 residues can
be modelled as a single collective phosphorylation, which will be
referred to as type Pa (Figure 2B), either present (corresponding
t oa l l3i n d i v i d u a lp h o s p h o r y l a t i ons) or absent (corresponding to
any other combination); this reduces the resulting number of
FOXO species from eight to two, i.e. by a factor of four. That
all three residues must be modified is shown by the results of
mutagenesis [74] and by the fact that FOXO6, which lacks one
of them, is not regulated by nuclear-cytoplasmic shuttling [79].
In addition, the same three residues are modified by SGK [80]
as well as Akt with similar effects; although the detailed kinetics
will be different, for modelling purposes we approximate them
as the same, i.e. all reactions are duplicated with Akt replaced
by SGK (these two enzymes are in any case difficult to
distinguish [62]) and the rates the same. Analogously, the three
A k ti s o f o r m sa r et r e a t e da sas i n g l eA k te n z y m e .
Other PTMs are simplified similarly (Figure 2B). Phosphory-
lation by CDK2 [81] and CK1 [82], although at different
residues, both lead to export to the cytoplasm and so are treated
as a single modification. Five phosphorylations by AMPK [11]
are considered as a single modification leading to increased
transcription. IKK modifies only a single residue, so needs no
simplification. The multiple modifications by JNK [83] and
MST1/STK4 [45] are again combined into one, and any
differences between the two enzymes are ignored. This is
reasonable because both enzymes are fully and quickly activated
by fairly low concentrations of H2O2 (below 100mM) (Lehtinen
Figure 1A, Essers Figure 1A); they then phosphorylate FOXO
within 30 mins (Lehtinen Figure 3A, Essers Figure 3A), which
results in its nuclear localization (Lehtinen Figure 4EF, Essers
Figure 4A) and transcriptional upregulation (Lehtinen Figure 5A,
Essers Figure 4B). Four acetylations [84] are combined into one
modification, as are two monubiquitinations [85]. Unlike the
other PTMs, it is possible that there could be competition
between the processes of acetylation and monoubiquitination,
since both PTMs are attached to Lys. However, the two
modifications are treated as independent in the model. Poly-
ubiquitination, leading to degradation, is treated as a one-step
process, although in fact a polyubiquitin chain must be built up
stepwise; this can be modelled in detail [86] but this degree of
sophistication was not included in the current FOXO model.
With these simplifications, there are effectively only a maximum
of 8 modifiers and 3 locations to consider, leading to a maximum
of 768 chemical species of FOXO if all PTM-addition reactions
are active. It is also of interest to know the total amount of
FOXO having a particular PTM, since this typically corresponds
to what can be measured via e.g. immunoprecipitation or a
Western blot; this is the sum of the copy numbers of all the
species that have that modification present, irrespective of the
other PTMs that they may contain. Therefore counter variables
Figure 2. Summary of FOXO PTMs. A: Sites and types of PTMs; and modifying enzymes; based on figure 2 of Calnan and Brunet 2008 [54].
B: Simplified set of collective PTMs and their effects.
doi:10.1371/journal.pone.0011092.g002
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reactions but simply sum appropriate subsets of the FOXO
species.
We now turn to the second problem, that of addressing the
kinetics of the reactions in which these species are involved. First,
consider the reactions involved (Figure 3). A particular FOXO
species may be phosphorylated by any of the five types of kinase in
Figure 2B and desphosphorylated by the corresponding phospha-
tase (Figure 3A). In this model, only a single phosphatase is
included that may catalyse any dephosphorylation reaction.
FOXO may also be acetylated by the CBP/P300 enzyme and
deacetylated by SIRT1 (Figure 3B), monoubiquitinated and de-
ubiquitinated by USP7 (Figure 3C), polyubiquitinated by the SCF
complex (or MDM2) and the resulting polyubiquitinated form
degraded (Figure 3D), translocated between cytoplasm, nucleus
and a DNA-bound state (Figure 3E), and synthesised (Figure 3F).
It may not be necessary to consider all these reactions as being
active simultaneously (indeed in this paper we do not consider
more than two or three different reactions being active at any
time), but the structure of the model allows them all to be so.
When the FOXO is bound to DNA, it stimulates the production of
the mRNA for each gene that it regulates; we assume that there is
also a ‘‘basal’’ production of this mRNA, a translocation of the
mRNA to the cytoplasm, where it may be degraded or translated
to protein, which may itself be degraded. Only in its own synthesis
reaction does the FOXO represent a single species in the model,
since it is synthesised in the cytoplasmic compartment without any
PTMs; otherwise it may already have any combination of the
PTMs applied by any of the other reactions, and may also be
present in any compartment. Hence, up to several several
thousand reactions interconverting FOXO species must be taken
into consideration. However, the reactions change only one of the
PTMs at a given step, i.e. each FOXO species can be converted
into only nine others. These pre-existing modifications will,
however, in general affect the rate constants for the forward and
backward steps. Usually, the way that multiple modifications
interact has not been measured in detail. In the model described in
this paper, the process has been treated simply by multiplying the
effects that each of the PTMs has in isolation on the relevant rates.
These effects are therefore modelled as parameters, which will be
referred to as Multiplicative Factors (MFs) subsequently, that multiply
the ‘‘basal’’ rate, For example, for a species with both Akt and
JNK phosphorylations, the effect on translocation is the basal
rate6MF due to Akt6MF due to JNK. This is clearly likely to be a
fairly gross approximation, but it is necessary to enable the model
to be parameterized; its justification will thus be in the empirical
validity and usefulness of the model. Of course, as most detailed
measurements are made, it will be possible to modify the model to
incorporate them.
For the transcription reactions represented in Figure 3G, the
number of reactions in the model would also be multiplied by the
number of FOXO-regulated genes. Currently, though, transcrip-
tion is considered to be that of only two genes, SOD2 (MnSOD)
and InsR, with identical kinetics. Transcription results are shown
only for SOD2.
For many of the regulatory reactions included in the model,
there are not explicit time courses, or only a few points. They are
modelled by mass-action kinetic equations of the following form:
Figure 3. Fundamental reaction types in the model. A: phosphorylation/dephosphorylation; B: acetylation/deacetylation: C: monoubiquitina-
tion/deubiquitination; D: polyubiquitination; E: translocation between cytoplasmic, nuclear and DNA bound states; F: synthesis; G: FOXO-dependent
protein synthesis.
doi:10.1371/journal.pone.0011092.g003
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v1
B : v1~kaEaA
B
v2
A : v2~kbEbB
dA
dt
~{v1zv2
dB
dt
~{
dA
dt
In these equations, A and B represent FOXO species with different
PTMs, and the forward and back reactions occur at rates v1 and v2,
catalysed by enzymes Ea and Eb. The experimental information often
amounts to a knowledge of (A/B)eq and some idea of the relaxation
time, from an experiment when one of A and B is initially at very low
concentration, then the enzyme that produces it is activated. From
the rate equations, first with the time derivative equal to zero, and
second with one of A or B (near)-zero, it is simple to see that this
determines pseudo-first order rate constants, k9a=k aEa and k9b=k bEb.
T h e n ,w ec h o o s ea p p r o p r i a t ev a l u e sf o rt h ec o p yn u m b e ro fEa and
Eb in the range of 10
4 to 10
5 when fully activated (10
5 is typical of Akt
when stimulated by insulin [87]); and set the second order rate
constants ka and kb accordingly, as shown in Table 1.
Transport processes are modelled with first-order kinetics:
A
v1
B : v1~ktr1A
B
v2
A : v2~ktr2B
Where A and B represent FOXO species in different compart-
ments, and the first order rate constants ktr1 and ktr2 can be found
from the relaxation kinetics. The rate constants for transport
processes are given in Table 2.
We have assumed that at the levels of ‘‘high active kinase’’ (10
4
molecules or more) the rates are high (half-life of a few minutes)
compared to processes like the relocation/degradation/transcrip-
tional output of FOXO. This is true of Akt-phosphorylation [27]
and is typical of phosphorylation processes, (though perhaps less so
of acetylation).
For the transcriptional outputs, the relevant reactions are
w
vbt
gmn : vbt~kbasalt
w
vft
gmn : vft~ktranscr(A)A
gmn
vmt
gmc : vmt~kexpgmn
gmc
vmd
w : vmd~kmdeggmc
w
vts
gpc : vts~ktranslgmc
gpc
vpd
w : vpd~kpdeggpc
Where w is null, gmn is the mRNA in the nucleus of gene g
(currently either SOD2 or InsR), gmc is the cytoplasmic mRNA of
gene g, gpc is the cytoplasmic protein corresponding to gene g, and
A is a DNA-bound FOXO species. The first- or zero-order rate
constants are given in Table 2.
A python script was written to generate the species and
reactions: this script is available as supplementary Dataset S2. To
comply with modelling standards and simplify exchange and re-
use, SBML [88] is used to represent the model; but, as a further
simplification, rather than generating SBML directly, the python
script produces output in SBML-shorthand [89], a more
compressed and human-readable format which nevertheless can
be converted without loss of information to SBML.
Simulations were carried out using the gillespie2 stochastic
simulator in stand-alone mode and also through BASIS, which
provides a web interface to gillespie2 and a database to store the
results [73,90]. Analysis was also carried out using R. Sensitivity
analysis was performed with COPASI [91].
As we have said above, the kind of equations relating to
fractional locations or degrees of up/down regulation do not
permit the number of molecules involved to be known exactly.
The initial number of FOXO molecules of all species was set to be
1000. This is probably an underestimate, but is the approximate
number of consensus FOXO binding sites, GTAAACAA [92],
within 1 kbase of the complete set of transcription start sites in the
genomes of the mouse and fly. This number is large enough that
the difference between a stochastic and deterministic simulation is
often unimportant; however, in this case, the large number of
different FOXO species means that the copy number of each
species can still be low – a situation that will arise commonly if
Figure 4. Behaviour of the model compared to experiment. A: total levels of nuclear FOXO in experiment (black) and simulation (grey) under
conditions when Akt is inhibited (data from Biggs et al. [75] fig 1 D/K; CV1 cells treated with wortmannin, simulation with active Akt=10), low (data: Biggs
et al. fig 1B/I; cells serum starved, simulation: Akt=1.75610
3), high (data: Biggs et al. fig 1 A/H: cells growing asynchronously in serum, simulation:
Akt=3610
4), and hyperactive (data: Biggs et al. fig 1F/M: constitutively active PI3Kinase, simulation Akt=6610
5). B: kinetics of transport of FOXO to
cytoplasm. Experiment [75]: CV1 cells are serum-starved then growth factors are provided. Simulation: pre-equilibrated for 2 h with Akt=2610
3,t h e nA k t
increased to 2.5610
4 at t=0. C: FOXO synthesis and degradation. Red: Expt: insulin 0.1 nM, MG132 10 mM; model: Akt=10
5, Proteasomes=0. Black: Expt:
serum-starved, model: Akt=100, Proteasomes=10
3),blue: Expt:insulin 0.1 nM; model: Akt=10
5, Proteasomes=10
3). Experimental datataken fromHepG2
cells (Matsuzaki et al 2003 [78]). D: Acetylation protects FOXO from degradation. Data points from bTC-3 cells (figure S5 in Kitamura et al [97]). Black: SIRT
high (copy number 10
3), CBPP300 low (10); Red: SIRT moderate (200), CBPP300 active (10
3); Blue: SIRT low (10), CBPP300 high (10
3). Synthesis is inhibited
(E2F1=0) and Akt active (10
5) in all simulations. E: degradation is accelerated by IKK activation: experimental datafrom MCF7 cells, from Hu et al [98] figure
5F, simulation: IKK=10
5.F:Effectofacetylationontranscription:experiment:(fromMatsuzakietalFig1B[99])FOXO1-mediatedtranscriptioninHepG2cells
of 36IRS-MLP-luc by wild-type, 3KR (acetylation-resistant) and 3KA (acetylation-mimic); simulation: nuclear SOD2 mRNA with copy number of
CBPP300=10
3, copy number of SIRT1=10
3 (50:50),CBPP300=10, SIRT1=10
3 (deAc(etylated)),andCBP/P300=10
3, SIRT1=10 (Ac(etylated)); normalized so
thattranscriptionfrom50:50=transcriptionfromWT.G:Upregulationoftranscriptionby AMPK:Experiment:Greeretalfigure7Aii,transcriptionof GADD45
with AMPK active and WT FOXO3 or 6A mutant (AMPK-phosphorylation-resistant); simulation: AMPK=10
5 or AMPK=100.
doi:10.1371/journal.pone.0011092.g004
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and JNK inactive (JNK=0). The PP2A level is 10
4. At t=60 min FOXO is set to high activity (5610
4); the PP2A level is 10
4. At t=120min the level of
active JNK is also set to 5610
4 (times of high kinase activity shown by dosing bars below the plots). The graph shows the total amount of FOXO and
Modelling FOXO Regulation
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copy number of mRNA species for the transcribed gene is low. For
both these reasons a stochastic representation is more appropriate
than a deterministic.
Results
Fitting the Model to Experimental Data
The first regulation of FOXO to be discovered was its Akt-
phosphorylation and translocation between nucleus and cyto-
plasm. Simply stated, in the absence of Akt-activation, FOXO is
primarily nuclear, while activation of Akt, usually by the insulin-
signalling pathway, leads to sequestration of FOXO in the
cytoplasm. Experimentally, FOXO localization is usually mea-
sured as the fraction of cells having FOXO mostly nuclear, mostly
cytoplasmic or both nuclear and cytoplasmic, as determined with
fluorescent-labelled FOXO. In the current model, the fraction of
FOXO in the nuclear or cytoplasmic compartment will be treated
as equivalent to the experimentally determined fraction of cells
having FOXO mostly nuclear or cytoplasmic. Those cells which
are experimentally observed to have FOXO both nuclear and
cytoplasmic are counted together with those where it is wholly
cytoplasmic (an equal division between nuclear and cytoplasmic
was also considered, but the assignment to cytoplasm gives a better
fit). In the model the total nuclear FOXO is simply the sum of that
in the nuclear and DNA-bound compartments. The basal rate of
redistribution is ,0.1 min
21, to give a half-life of the order of
10 minutes, with the cytoplasmic-nuclear rate slightly higher, and
the nuclear-cytoplasmic lower, for unmodified FOXO, to give an
equilibrium favouring the nuclear form. The basal rates of DNA
binding and unbinding are chosen so that, of the total nuclear
FOXO, about two-thirds is DNA-bound and one-third nuclear
but not bound to DNA.
In Figure 4A we show the generally good agreement between
the total nuclear FOXO fraction in experiments in CV1 cells
(Figure 1A–N [75]) and simulation, under gradually increasing
levels of Akt activation, corresponding in experiment to inhibition
of PI3K with wortmannin, serum-starvation, provision of growth
medium, and constitutive activation of PI3K. (PI3K is a kinase
upstream of Akt in the IIS pathway).
In Figure 4B a timecourse of the redistribution of FOXO from
nuclear to cytoplasmic upon Akt activation is shown. In the
experiment (Biggs et al. Figure 1O [75]), CV1 cells are serum
starved for 2h and then stimulated for 1h with IGF-1. Using the
model, the best fit to this is obtained with active Akt of 2610
3 in
the pre-equilibration level, which is then increased to 2.5610
4 to
correspond to the IGF stimulation. The experiment lags slightly
behind the simulation result at around 5 or 10 minutes, but this is
its levels in the nuclear, DNA-bound and cytoplasmic compartments, as a fraction of total FOXO at t=0.B: same experiment as A, the level of SOD2
mRNA in nuclear and cytoplasmic compartments is shown C: same experiment as A, the level of SOD2 protein is shown. D: fraction of cytoplasmic
and total nuclear (nuclear+DNA-bound) FOXO, as a function of Akt copy number, for different levels of JNK. PP2A level is 10
4. E: as for D, PP2A=100.
doi:10.1371/journal.pone.0011092.g005
Table 1. Parameters of the model (FOXO synthesis/degradation and PTM addition/removal processes).
process
2u rate constant
(#min
21) Enzyme Enz #
1u rate const
(min
21)
PTM
modify-ing rate Rate MF Reference
Synthesis (NULLRFOXO) 0.0055 E2F1 100 5.5 [78] Figure 1
Degradation (FOXO_pUbRNULL) 1610
24 Protea-some 10
3 0.1 ‘‘
FOXORFOXO_Pa 5610
25 Akt 10
4 0.5 [27] Figure 1C
FOXO_PaRFOXO 5610
25 PP2A 10
4 0.5 ‘‘
FOXORFOXO_Pb 5610
25 CDK2 10
4 0.5 [81,82]
FOXO_PbRFOXO 5610
25 PP2A 10
4 0.5 ‘‘
FOXORFOXO_Pc 5610
25 AMPK 10
4 0.5 [11]
FOXO_PcRFOXO 5610
25 PP2A 10
4 0.5 ‘‘
FOXORFOXO_Pd 5610
25 IKK 10
4 0.5 [98]
FOXO_PdRFOXO 5610
25 PP2A 10
4 0.5 ‘‘
FOXORFOXO_Pe 5610
25 JNK 10
4 0.5 [83]
FOXO_PeRFOXO 5610
25 PP2A 10
4 0.5 ‘‘
FOXORFOXO_Ac 1610
24 CBP 10
3 0.1 [96,99]
FOXO_AcRFOXO 1610
24 SIRT 10
3 0.1 ‘‘
FOXORFOXO_mUb 2610
24 E3 10
3 0.2 [85]
FOXO_mUbRFOXO 2610
24 USP7 10
3 0.2 ‘‘
FOXORFOXO_pUb 1610
26 SCF/MDM2 10
3 10
23 [78] Figure 1; also [94]
Akt-Phos Pa 3 [78] Figure 1
IKK-Phos Pd 6 [98] Figure 5F
Acetyl Ac 0.033 [97] Figure S5
Rate constants of FOXO synthesis/degradation and PTM addition/removal processes. For a given process, the first-order rate constant is given, and, for enzyme
catalysed reactions, a derived second-order constant and the putative enzyme molecule number that produced it. Only the product of these, the first order constant, is
related to experimental measurements. Where appropriate, a list is then given of a series of multiplicative factors (MFs) which may modify the rate for the process,
depending on the presence of a another particular PTM in the FOXO species.
doi:10.1371/journal.pone.0011092.t001
Modelling FOXO Regulation
PLoS ONE | www.plosone.org 9 June 2010 | Volume 5 | Issue 6 | e11092reasonable given that that in the simulation the level of active Akt
is set directly whereas in the experiment it must be activated
through the IIS pathway, with a delay of the order of a few
minutes.
Now let us consider the synthesis and degradation of FOXO.
This was first studied in detail in experiments on HepG2 cells by
Matsuzaki et al [78]. These experimental results, together with
model output, are shown in Figure 4C. For synthesis, it has been
shown that, if the proteasome is inhibited with MG132, the
amount of FOXO1 increases in the cell by 20% in 6h. Taking the
equilibrium copy number of FOXO of all chemical species to be
1000, the rate of increase of FOXO is then approximately 5.5
molecules min
21, shown in Table 1 as a pseudo-first order rate
constant. Breaking this down in to a second-order constant 6the
copy number of the E2F1 transcription factor, and choosing this
copy number=100, gives the basal value of the rate constant
0.0055 min
21. Then, without proteasome inhibition, the amount
of FOXO in the cell was quantified with and without insulin
stimulation, i.e. with and without Akt activation, over 12h.
Although proteasomes are present in the nucleus, it has been
convincingly shown that degradation of FOXO occurs only in the
cytoplasm [78,94]. It has also been shown that phosphorylated
FOXO is degraded faster. Assuming the basal synthesis level is
maintained subsequently, we simultaneously fitted the pseudo first-
order polyubiquitination and degradation rates and the MF
multiplying the rate at which Akt-phosphorylated FOXO is
degraded compared to unphosphorylated. The best fit was
obtained with first order rate constants of 10
23 min
21 for
polyubiquitination, 0.1 min
21 for degradation, and an MF of 3.
Taking the copy numbers of the modifiers to be 10
3 for both the
total of ubiquitin ligases (SCF+MDM2) and the proteasome, this
gives second order rate constants of 10
26 and 10
24 min
21. With
these parameters, Figure 4C shows that, when degradation is
inhibited, the amount of FOXO in the cell increases despite the
activity of Akt (data in red), whereas, without inhibition of
degradation, FOXO molecule number decays very slowly when
Akt activity is low (data in black), or with a half-life of about 6h
when Akt activity is high (data in blue).
Other PTMs significantly modulate the degradation of FOXO.
Acetylation is one of these, and is of particular interest because of
the suggestion that the FOXO- and histone- deacetylase, SIRT1,
may also modulate organism lifepan. The timescale of both
acetylation and deacetylation is of the order of 10 minutes when
highly activated. This is shown in van der Horst 2004 [95]
Figure 4, in response to high concentrations of H2O2, 200 and
500 mM, that activate CBP/P300 and fully acetylate FOXO4 in
Table 2. Parameters of the model (transport of FOXO and processes involving FOXO-regulated genes).
process
2u rate constant
(#min
21) Enzyme Enz #
1u rate const
(min
21)
PTM modify-ing
rate Rate MF Reference
CytoplasmRnuclear transport - - - 0.1/0.55=0.182 [74], [75]
Akt-Phos Pa 0.1 [75]
CDK2-Phos Pb 0.5 [81] Figure 3A
IKK-Phos Pd 0.5 [98] Figure 1
JNK-Phos Pe 10 [83]
mUb 10 [85]
NuclearRcytoplasm transport - - - 0.160.55=0.055 [74], [75]
Akt-Phos Pa 10 [75]
CDK2-Phos Pb 2 [81]
IKK-phos Pd 10 [98]
JNK-Phos Pe 0.1 [83]
mUb 0.1 [85]
NuclearRDNAbound transport - - - 0.25 [76]
Akt-Phos Pa 0.5 [77] Figure 6B
Acetyl Ac 0.5 [99] Figure 1D
DNAboundRNuclear transport - - - 0.2560.5=0.125 [76]
FOXO- simulated
Transcription ktranscr
0.3 FOXO #(DNAbound
FOXO)
[19]
CDK2- Phos Pb 0.1 [81]
AMPK-Phos Pc 2.0 [11] Figure 7A
(ii)
Basal transcription kbasalt - - - 3 [100]
RNA export kexp - - - 0.22 [100]
RNA translation ktransl - - - 1.23 [100]
RNA degradation kmdeg - - - 5.622 [100]
Protein degradation kpdeg -- -1 . 9 610
23 [100]
Rate constants of FOXO translocation reactions and transcription, translation and degradation processes of FOXO-regulated genes/proteins. The first-order rate constant
is given for these processes, except for basal transcription, which is zero-order. Where appropriate, a list is then given of a series of multiplicative factors (MFs) which
may modify the rate for the process, depending on the presence of a particular PTM in the FOXO species.
doi:10.1371/journal.pone.0011092.t002
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acetylation is still low after 1h but is more or less complete after
4h). Hence, it is reasonable to choose pseudo-first-order rate
constants of ,0.1 min
21, and we make the choice of the copy
number of CBP/P300 and SIRT1 to be 10
3 when fully activated,
and a second order rate constant of 10
24 for each reaction. SIRT1
and CBP/P300 are mostly nuclear [96], so in the model these
reactions do not occur in the cytoplasmic compartment.
Regarding its interaction with degradation, experiments by
Kitamura et al [97] on FOXO1 in betaTC3 cells (pancreatic
cells, in which Akt is permanently activated by endogenous insulin)
show that acetylation exerts a strong protective effect against
degradation. This is shown in Figure 4D, where model output is
fitted to experimental data. This fit is obtained with acetylation
reducing the rate of polyubiquitination by a factor of 30, and
SIRT and CBP/P300 levels that give high, medium and low levels
of acetylation.
Another PTM that affects degradation, this time accelerating it,
is phosphorylation by IKK. Again, phosphorylation is chosen to be
a rapid process in comparison with degradation. The fit in
Figure 4E is produced by a saturating level of IKK activation, with
a MF of 6 for polyubiquitination of IKK-phosphorylated FOXO.
IKK phosphorylation also leads to FOXO translocation to the
cytoplasm even if Akt is low. This leads to good agreement with
experimental data from Hu et al on FOXO3 [98].
Acetylation also affects transcription, as shown in Figure 4F,
where experimental measurements [99] of transcription by wild-
type FOXO1, an acetylation-resistant 3KR mutant and an
acetylation-mimicking 3KA mutant are compared with transcrip-
tional output of the model with SIRT and CBP/P300 levels that
produce 50% of FOXO acetylated, mostly deacetylated, and
mostly acetylated. The DNA-binding of the acetylated form is
decreased by a factor of two, as was measured directly [99]. The
agreement is reasonable, especially considering that the mutants
may in any case not behave identically to the acetylated or
deacetylated forms.
FOXO may also be modified by AMPK, with modulation of
transcription but not subcellular localization [11]. Again, we
assume that AMPK-phosphorylation is a rapid process, and when
fully phosphorylated, the FOXO-stimulated transcription rate is
increased by a factor of two. As shown in Figure 4G, this is in good
agreement with the experimental data for transcription from
several genes including GADD45, though the experimental result
seems to be gene dependent, a level of complication not included
in the model currently. In Figure 4G, experimental data for
transcription of GADD45 by WT FOXO3 with AMPK activated,
and transcription under the same conditions from a 6A mutant of
FOXO that is not phosphorylated by AMPK, is compared with
simulation data with AMPK fully active (copy number 10
5) and
mostly deactivated (copy number 100).
JNK-phosphorylation broadly opposes the effects of Akt-
phosphorylation, and is discussed in the subsection on scenarios
of multiple FOXO regulation below. Other modifications such as
CDK2-phosphorylation and monoubiquitination have similar
effects, causing alteration of the nuclear-cytoplasmic equilibrium
and FOXO-mediated transcription. They can be modelled
similarly (data not shown).
Several parameters of the model relate to transcription of
mRNA, its transport to cytoplasm, translation to protein and and
degradation; and also to the degradation of the protein. Lacking
absolute quantification of protein or mRNA level, or measurement
of mRNA or protein lifetime, we have used generic values [100].
SOD2 protein level seems to be upregulated to about the same
degree as mRNA on a timescale of 1 day [19], consistent with a
protein half-life of up to about 8 hours. Only the transcription rate
depends explicitly, in certain cases, on the PTM state of FOXO.
In the future these parameters could be made gene-specific as
required. Example models (in SMBL format) producing curves in
Figure 4C–E are given as supplementary datasets S3, S5 and S7.
These datasets, together with all other supporting information, are
also available in the single dataset S9.
Sensitivity
We have investigated the sensitivity of the concentrations of the
species of the model as a function of the parameters, using
COPASI [91], in deterministic simulations of the models used in
the fitting described above. The sensitivity was calculated at a
certain time point, particular to each simulation, where initial
transients had died away (most of the enzyme-catalysed PTM
adding/removing reactions had come into pseudo-equilibrium,
while the concentration of SOD2 protein, which has a longer
timescale, was near a stationary point). It was not appropriate to
find the long-time equilibrium as in several of the scenarios
simulated the model did not have a non-trivial steady state. Scaled
sensitivities, i.e. (k/X) dX/dk where X is a concentration and k a
parameter, were considered. Examples of the detailed results are
available as supplementary Datasets S4 (corresponding closely to
the model S3), S6 (corresponding to S5) and S8 (corresponding to
the model S7). The most important parameters depend, of course,
on the regime that the model is in (which PTMs are active, etc):
sensitivities are low to those parameters which only affect reactions
in which the species involved are present at low concentrations. In
general, synthesis/Akt-phosphorylation and polyubiquitination
(but not degradation itself) and transport processes, especially
between nucleus and cytoplasm, tend to affect the FOXO
concentrations and the concentrations of the output gene, with
high sensitivities (of magnitude up to 1). Only a few FOXO
concentrations, and not the output gene concentrations, have a
high direct sensitivity to reactions involving acetylation/deacetyla-
tion. We remark that, although the results are sensitive to Akt-
phosphorylation and dephosphorylation, they are not sensitive to
an increase or decrease of both by the same factor, because these
reactions (and others of PTM addition and removal) occur on a
shorter timescale than other processes in the model such as FOXO
synthesis and degradation. Datasets S4, S6 and S8, together with
all other supporting information, are also available in the single
dataset S9.
Scenarios of Multiple FOXO Regulation
Having shown that experimentally-determined responses to
single and some multiple regulations can be reproduced by the
model, we now move on to study the behaviour of the model in
scenarios involving multiple regulations. A simple combination of
effects is shown in Figure 5A–C. A simulation has been pre-
equilibrated for 1 day, to allow the SOD2 protein to reach
equilibrium. Akt activation (starting at t=60 min and remaining
active for the rest of the simulation) causes FOXO translocation to
the cytoplasm; accordingly, transcription almost stops and the
cytoplasmic and nuclear concentrations of mRNA fall; the level of
the protein also begins to fall, although the effect is not very large
on a 1 hour timescale. After a further 60 minutes, JNK is
activated, and in large measure overrides the effect of Akt and
causes the FOXO to translocate back from the cytoplasm to the
nucleus. Once in the nucleus, however, it will be observed that the
ratio DNA-bound/nuclear is lower than before, and the FOXO
level is also slightly lower as some has been degraded while it was
cytoplasmic. Accordingly, although the mRNA level recovers
somewhat, it is not to its previous level, and the protein continues
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kinases is set to 10
5 when they are active. The PP2A level is 10
4
molecules, so the PTM that the kinases confer is present in about
80% of the FOXO molecules.
Experiments in which JNK is activated by H2O2 show an
interplay between the opposing effects of JNK and Akt; JNK tends
to override Akt (as in A–C) but if Akt activity is particularly high it
may override a low level of JNK activation [83]. Detailed dose-
response data that would enable a full parameterization is not
available, but Figure 5D and E show that the model can capture
these effects. As Akt increases it tends to drive FOXO to the
cytoplasm, but the effect can be reversed by JNK. It is interesting
to note the effect of reducing the activity of protein phosphatases:
in D the PP2A level is high (copy number 10
4), while in E it is
much lower. It is noteworthy that, with PP2A low and without
JNK, a lower level of Akt activation (in E compared to D) is
sufficient to drive FOXO to the cytoplasm, but also a lower level of
JNK activity suffices to retain it in the nucleus even at a high level
of Akt activation (compare the response to JNK=10
3). That
PP2A, JNK and Akt could all change together is a likely scenario,
because oxidative stress tends to inactivate protein phosphatases
due to their reliance on a catalytic cysteine that contains an easily
oxidised SH group.
Another example is shown in Figure 6, which shows the effect of
a short and long stimulation by Akt under different background
PTM states. This in-silico experiment was suggested by comments
made in Calnan and Brunet [54]; to our knowledge it has not been
experimentally investigated, so the simulation results constitute an
experimentally verifiable prediction made by the model.
First, consider the effects of short and long-term activation of
Akt alone, (Figure 6A–C). The system was pre-equilibrated at low
Akt for 2880 minutes (2 days) before the first period of Akt
activation. The last 360 minutes of this is shown in Figure 6, so
that the mainly nuclear (DNA-bound) location of FOXO is
apparent. At t=360, Akt is activated for 60 minutes (set by an
event from 100 molecules to 10
5). This initial burst of Akt
activation causes FOXO translocation to the cytoplasm and
transcription almost stops (Figure 6B). However, once active Akt is
reset to a low level (back to 100 molecules t=420 for the next
120 min) the FOXO rapidly relocates to the nucleus and
transcription resumes at almost the same level it had initially. A
second, longer period of Akt activation then follows (10
5 active Akt
molecules from t=540 for the next 720 min (12 hours) ), again
causing translocation of FOXO and almost halting transcription of
FOXO target genes. This pulse is long enough for the level of
FOXO to decline by more than half in the course of it, as a result
of polyubiquitination and resultant degradation of the cytoplasmic
FOXO. Hence, when the second pulse of high Akt activity ends (at
t=1260) and FOXO returns to the nucleus, the transcription level
(Figure 6B) is at first also less than half what it was before the Akt
pulse. The simulation is continued for a further 1 K days (until
t=3420), during which the transcription level recovers, as FOXO
is re-synthesised, though even at the end of this period it has only
just regained its initial level. Consequently, the level of SOD2
protein (with a half-life of 8h) also declines appreciably during the
long Akt pulse, and recovers only slowly thereafter. In this
simulation the copy number of CBP/P300 was set to 10 molecules
and SIRT1 to 1000, levels designed to ensure that acetylation is
slight, and the levels of other modifying enzymes were set to zero.
The same protocol of brief and prolonged Akt activity has a
different outcome if the FOXO is more strongly acetylated
(Figure 6 D–F), an effect which may be produced either by
increasing the level of active CBP/P300 and/or decreasing the
level of SIRT1; in this simulation the levels were CBP/
P300=1000, SIRT1=100 throughout the pre-equilibration
period and the timecourse shown, leading to 90% acetylation of
FOXO. E2F1 was reduced to ensure that the copy number of
FOXO was about the same in A and D. Acetylated FOXO binds
DNA less strongly, but it is also stabilized against polyubiquitin-
mediated degradation. As a consequence, the basal level of FOXO
mediated transcription is lower (only 75% of its level when FOXO
is unacetylated; Figure 6B vs Figure 6E) but almost none of the
FOXO is degraded during the long Akt pulse, so that when the
second pulse of Akt activity ends, transcription recovers almost
immediately to its basal level in this PTM background. Hence,
although equilibrium level of SOD2 is also lower, and it is
degraded as before during the long Akt pulse when FOXO is sent
to the cytoplasm, it recovers more quickly to its initial level
(Figure 6F cf Figure 6C).
This demonstrates how the model is capable of making
experimentally verifiable predictions of the effects of PTM-
inducing treatments applied according to various time-dependent
protocols.
Discussion
The model presented here provides a significant first step
towards a detailed model coupling ageing-related stress and
nutrient response pathways with the stress resistance. It also
provides an extensible modelling framework into which future
information could be integrated. Although complex, because of
the need to treat multiple chemical species, we believe that there is
no other approach that can integrate information from multiple
regulatory pathways into a single framework. We have shown that,
even without detailed up- and downstream pathways, it is capable
of reproducing experimental data on many features of FOXO
regulation. Moreover, in Figures 5 and particularly 6, we have
shown how the multiple regulations of FOXO alone can produce
complex spatio-temporal dynamics, such as the faster recovery of
antioxidant levels after the end of a long period when FOXO
acetylation is at a high level.
Despite the large amount of work done on FOXO transcription
factors, it is not easy to parameterize the model; time courses are
generally not available, and different organisms and different
tissues are widely used, so we have frequently had to argue by
homology between different tissues or organisms, though human
FOXO1 was the paralogue most often used and cell lines such as
CV1, HepG2, bTC-3 and MCF7 were used. Hence the fact that
we have referred to the species in the model as FOXO rather than
FOXO1 or some other specific paralogue.
The modifying processes have been represented by simple 2u
mass-action rate laws. This is a consequence of two factors: first,
there are few quantitative timecourses available, but more usually
a series of Western blots (sometimes only showing the presence or
absence of a treatment and an indication of the time over which
the change occurs). With this data, the forward and backward
rates of a first order process and its inverse can be estimated, but
the multiple constants of more complicated kinetics cannot.
Secondly, the simplification of combining multiple phosphoryla-
tions into a single collective modification leads naturally to simple
kinetics where the FOXO species appears linearly in the rate
expression; nevertheless it is likely that more detailed timecourses
would show that the kinetics do not follow this kind of behaviour.
For example, with multiple regulations, it is to be expected that the
fully phosphorylated form will appear as a concave-upwards
function of time, such as a cubic function when three
phosphorylations occur, in response to a step increase of the
enzyme producing it, rather than the linear timecourse of the 1u
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PLoS ONE | www.plosone.org 12 June 2010 | Volume 5 | Issue 6 | e11092Figure 6. The effect of brief and prolonged Akt activity interacting with degradation and acetylation. Before the start of the time course
in the figure, FOXO is pre-equilibrated for 2520 minutes to allow its target gene SOD2 to come into equilibrium, with Akt very weakly active (copy
number 100). A–C shows a simulation where acetylation is low (SIRT1=10
3, CBP/P300=10), whereas in D–E CBP/P300 is high (SIRT1=10, CBP/
P300=10
3) so that FOXO is 99% acetylated. As shown by the dosing bars, Akt is activated at t=360 min for 60 min, and again at t=540 min for
720 min. The panels show: (A,D): total FOXO and the amount in each compartment, as a fraction of the total at t=0; (B, E) mRNA in nucleus and
cytoplasm for the output gene SOD2; (C,F) SOD2 protein level.
doi:10.1371/journal.pone.0011092.g006
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delay in experiment. As detailed time course data becomes
available it may, therefore, be necessary to revise this assumption.
Transport into and out of the nucleus has also been represented
by simple first order processes with rates dependent on the PTM
state, when in fact the process is more complex, involving binding
of the FOXO to two 14-3-3 proteins, masking the Nuclear
Localization Signal, and its resultant export to the cytoplasm [62].
This export from the nucleus is itself a multi-step process,
involving binding to the nuclear pore complex and several other
cofactors. Again, this may alter the kinetics in some regimes. It is
interesting to note that the action of JNK in causing nuclear
localization occurs through multiple mechanisms: JNK phosphor-
ylates both 14-3-3 and FOXO, causing them to unbind from each
other in the cytoplasm, and also attenuates Akt activation by
phosphorylating IRS. The action seems to be evolutionarily
conserved, but the JNK-phosphorylation sites are conserved much
more highly in 14-3-3 than FOXO [63], so the effect is probably a
result of the 14-3-3 modifications. The model, in which 14-3-3 is
not explicitly represented, can capture this simply as a nuclear re-
localization response which is conserved even if the JNK-
phosphosites are not (cf. Figures 1A/2A).
The negative second derivative of the experimental curve of
FOXO molecule number against time (Figure 4C) suggests that
there is negative feedback inhibition of FOXO synthesis, though
this is not included in the current model. This may also explain
why acetylation does not seem to produce a large increase in
FOXO molecule number.
In general, the kinetics of the phosphatase-catalysed reactions
are much less certain that those of the kinase-catalysed reactions.
Most of the time they have not been studied in detail. Hence, we
have assumed a single ‘‘general phosphatase’’, assumed to be
PP2A, to reverse all the kinase-mediated phosphorylations in the
model.
When the localization of FOXO alters experimentally in
response to changes in PTM, it is experimentally observed that
there is a change in the fraction of cells in the population having
FOXO primarily nuclear, primarily cytoplasmic, or present in
both compartments (see for example Figure 3 of Brunet 1999 [74],
Figure 1 of Biggs et al. 1999 [75] or Figure 4 of Essers et al. 2004
[83]). Although the stochastic modelling carried out here means
that there is continuous fluctuation in the amount of FOXO in the
various compartments of the model (cytoplasm, nuclear and DNA-
bound), we found that the fluctuation is usually small, about 10
molecules, i.e. 1% of the total amount of FOXO, and the average
number of FOXO molecules in each compartment varies
smoothly as the PTM level alters. This seems somewhat different
to the behaviour reported about cell cultures; however it is likely
that there is in fact a continuous variation in the amount of FOXO
in nuclear and cytoplasmic compartments, but the impossibility of
quantifying this amount means that the simple three-state
classification must be adopted, and all cells where FOXO is
present in more than small amounts in both compartments will be
classified as having FOXO nuclear+cytoplasmic, whether the ratio
be 0.2:0.8 or 0.8:0.2. Turning to the question of the differences
between cells in a population, it might at first be thought that the
experimentally observed behaviour corresponds to stochastic
fluctuations in the response of particular FOXO molecules.
However, since in the model these fluctuations were very much
smaller, and moreover since it appears from the published data
that the FOXO localization in a particular cell is more or less
stable in time, we believe this is unlikely to be the case. It could
instead be a consequence of differences between cells in the
expression level of upstream components of the insulin signalling
pathway. In future, heterogeneity in a population of models could
be studied, and/or alternative model architectures, such as positive
feedbacks, could be investigated to try to increase the observed
fluctuations to obtain behaviour closer to that seen experimentally.
These are currently beyond the model boundaries.
Several details of the reactions which could potentially affect
the model’s behaviour have been omitted. For example, cofactors
essential for the formation of PTMs, such as ATP, ubiquitin,
Acetyl-CoA and NAD+, are not explicitly included in the model.
We also remark that, although the model reproduces the
experimental result that acetylation downregulates FOXO-
mediated transcription, and deacetylation upregulates it
(Figure 4F), the situation experimentally is more complex than
this suggests, with transcription found to vary in a gene-
dependent way, some genes being downregulated and some
upregulated [96,99,101]; reviewed in [102]. A plausible expla-
nation for this is given by Daitoku et al [84], whose work showed
that histone acetylation and deacetylation is carried out, with an
effect on transcription, by the same enzyme pair that modifies
FOXO. This could be handled by extending the model to include
acetylated and deacetylated states for the FOXO-regulated genes
as well as for FOXO itself. Transcription downstream of FOXO
is not the focus of this paper and has been limited to two genes.
However, the model could be easily extended to include multiple
genes, with gene-specific values of the basal and FOXO-
stimulated transcription rate.
In addition to its direct action as a DNA-binding transcription
factor, FOXO may bind to other TFs and modulate their activity.
This occurs for example with nuclear receptors such as HNF-4
[103] and ER (Estrogen receptor) [104,105], as well as PR, GR,
RAR and TR [104]. FOXO seems usually to reduce the
transactivation function of the other TF but may also increase it,
as the case of RAR and TR. In a similar way, FOXO may also
bind to another TF acting as a transcriptional repressor and relieve
this repression, as seems to happen with p53 repression of SIRT1
transcription [29] or Cs1 repression of Hes1 [106]. Behaviour of
this kind could be treated by extending the model to introduce
reactions in which FOXO species, probably that subset which is
nuclear but not DNA-bound, bind to other TFs to form species
representing the FOXO-TF complexes. Depending on the other
TF and the gene, the resulting complexes themselves could be
assigned low or no transcriptional activity, corresponding to
FOXO acting as a transcriptional repressor, or a higher
transcriptional activity than the other TF alone, corresponding
to FOXO acting as a transcriptional co-activator. It was found in
Hirota et al. [103] that the binding between FOXO and HNF-4
itself depends on the phosphorylation state of FOXO; this could
be treated very naturally in the modelling framework used here.
The cost in increased complexity of the model depends on the
other TF. If it can be treated simply the cost would be similar to
that of adding an extra class of PTM to FOXO, but if it has many
states itself (representing different localizations, different PTMs etc)
then the number of species representing complexes is the product
of the number of FOXO species and the number of species of the
other TF, and care would need to be taken to keep this
manageable. Similar considerations arise if the number of
regulated genes in the model is also high.
Even the large number of regulations considered in this paper
does not exhaust FOXO’s repertoire. A potentially important
omission in the current model is that of additional stress response
phosphorylations made by p38 MAPK (MAPK14) and ERK
(MAPK1), which may not be synonymous in their effect to those
by JNK. It has been shown that ERK and p38 MAPK modify
mouse FOXO1 [107], and the p38 MAPK orthologues pmk1-3
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modification by p38 is similar to that by JNK, i.e. translocation of
FOXO to the nucleus; however there is some evidence that ERK
in mammals has a different effect, causing increased MDM2-
mediated degradation and possibly translocation from nucleus to
cytoplasm (although inhibition of MEK, upstream of ERK, fails to
reverse this [109]). At the cost of further increasing the number of
species in the model, these effects could be included by adding
additional PTM states within the framework of the existing model
and choosing appropriate rate constants to reproduce experimen-
tal data as far as possible. FOXO can also be methylated [110], a
modification that reduces its Akt-mediated phosphorylation. In
addition, FOXO1 appears to be phosphorylated by ATM/ATR
[111] while FOXO3 is itself important for activation of ATM/
ATR [112,113]; these modifications may be included in future
versions of the model. Updating of the model would currently be
done manually, though the process would be simplified by the
work already done in extracting relevant data from publications
and developing fitting protocols. Moreover, parameters of
processes not related to the PTM to be added or modified should
remain unchanged. However, a way of computationally ascer-
taining the correct simplifications of the PTM set would clearly be
desirable, and research is proceeding currently that addresses
related problems. This has been mainly done on genetic and
metabolic networks. In metabolic networks important simplifica-
tions arise because the behaviour of steady-states is studied rather
than kinetics, and there are stoichiometric constraints on the
reactions. Attempts have already been made to generate genome-
scale models [114,115], and even to do so automatically using
annotations [116,117]. Applying similar approaches to these to
kinetic modelling may become feasible in the near future, though
this will require both theoretical developments [118] and high
throughput experiments with data generated in machine-readable
formats [119]. One way of developing the FOXO model
automatically would be, given some sets of data and a trial model,
to use a Monte Carlo approach to alter that model by adding or
deleting categories of PTMs and re-allocating reactions between
them, and then re-fitting to optimize parameters within each
model. Similar approaches have been tried to investigate the
robustness of gene regulatory networks in simulations of evolution
[120].
Similar approaches to generating multiple chemical species by
enumerating combinations of PTMs have been implemented
several times previously (Cellerator [121] StochSim [122]
BioNetGen, [123]). The approach adopted here to the problem
of modelling a molecule with multiple modifications, and
estimating parameters in such models with many species, is
similar to that of ‘‘rule-based modelling’’ (see papers by Hlavacek
et al. [93,124] and Faeder et al. [125] and references therein), and
a similar method of reducing multiple modifications to a single
collective modification has also been used previously [126]. We
remark that multistate species (i.e. addition of multiple PTMs to a
base species) will be supported by the non-core SBML Level 3
package ‘‘multi’’ which will be of great benefit for this type of
modelling. Developments in rule-based modelling particularly may
also be relevant to the question of updating the model, and indeed
new algorithms that allow reactions to be generated as required
‘‘on-the-fly’’ rather than enumerated beforehand may enable the
lifting of the requirement that multiple modifications be combined
[127,128].
The scripting/rule-based modelling approach to generating
reactions is applicable to other proteins that undergo multiple
regulations in a similar manner, for example the insulin receptor
substrate IRS-1 [129–131] and the C elegans transcription factor
SKN-1 (orthologous to NRF TFs in higher organisms) [132].
Following on from this, we remark that several other TFs are
indeed, like FOXO, regulated by multiple PTMs, including the
tumour suppressor p53 (UNIPROT accession P04637 for the
human protein), which can undergo modifications including
phosphorylation (by multiple kinases including ATM/ATR),
acetylation, methylation and ubiquitylation at least 17 sites
[133]. There have been many other papers [70,71,134,135]
modelling aspects of the behaviour of p53, though these have
mostly concentrated on the negative feedback control through its
transcription of the ubiquitin ligase MDM2 and resulting
degradation, which can produce oscillations in protein concentra-
tion. p53 is usually represented in these models by more than one
species, which may correspond to different PTM states. For
example, in the papers by Proctor et al. and by Puszynski et al.
there are both an inactive and a transcriptionally active form of
p53, the latter phosphorylated in response to DNA damage. These
can be viewed as omitting certain modifications that are irrelevant
to the particular purpose of the model and considering the others
as a single collective modification, in a similar way to how the
multiple Akt-modifications of FOXO were treated here. However,
to understand other aspects of the tumour suppressor function of
p53, for example the interplay of responses to DNA damage and
hypoxia, the interaction of multiple PTMs may be important and
could be tackled by modelling using methods similar to those
employed here.
To summarize, this FOXO model provides a framework into
which future measurements can be fitted, and provides a central
component for more complex models integrating the multiple
upstream pathways and the downstream events that follow from
the transcription of the multiple FOXO-regulated genes. We
have demonstrated that, even alone, it demonstrates complex
spatio-temporal regulations: in particular, the behaviour shown in
Figure 6 may have implications for stress-resistance transcription.
If FOXO is not acetylated, the long-time activation of Akt by
insulin-like signalling may lead to sufficient degradation of
FOXO that recovery of FOXO mediated stress-resistance
transcription would be slow (in the simulation in Figure 6, this
follows simply from Akt deactivation; but it could also be the
result of a JNK activation to override the Akt, as in Figure 5).
However, if the FOXO is simultaneously protected by acetyla-
tion, FOXO is degraded much less and transcription recovers
more rapidly. In the current model, the absolute level of
transcription from acetylated FOXO was slightly slower, but this
could be a gene-specific effect. In combination with detailed
models of the upstream and downstream pathways, this work will,
we anticipate, provide insight into the interplay of ageing,
nutrition and stress, and form the basis for a modelling approach
connecting metabolic pathways relating to ageing, energy usage
and stress with life history theory. This model represents an
essential first step.
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Dataset S5 SBML model file for the simulation in figure 4D
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Dataset S6 Sensitivity analysis (tab-delimited file) for model
S5.xml.
Found at: doi:10.1371/journal.pone.0011092.s006 (0.07 MB
TXT)
Dataset S7 SBML model file for the simulation in figure 4E -
Akt low, IKK high, normal synthesis/degradation.
Found at: doi:10.1371/journal.pone.0011092.s007 (0.13 MB
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Dataset S8 Sensitivity analysis (tab-delimited file) for model
S7.xml.
Found at: doi:10.1371/journal.pone.0011092.s008 (0.07 MB
TXT)
Dataset S9 All above supporting information (S1–S8) in single
zip archive: multiple sequence alignment of FOXOs (aln), python
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